128 related articles for article (PubMed ID: 9209899)
1. A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone.
Bergqvist A; Jacobson J; Harris S
Gynecol Endocrinol; 1997 Jun; 11(3):187-94. PubMed ID: 9209899
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis.
Bergqvist A;
Gynecol Endocrinol; 2000 Dec; 14(6):425-32. PubMed ID: 11228063
[TBL] [Abstract][Full Text] [Related]
3. Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group.
Agarwal SK; Hamrang C; Henzl MR; Judd HL
J Reprod Med; 1997 Jul; 42(7):413-23. PubMed ID: 9252932
[TBL] [Abstract][Full Text] [Related]
4. A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone.
Eldred JM; Haynes PJ; Thomas EJ
Clin Endocrinol (Oxf); 1992 Oct; 37(4):354-9. PubMed ID: 1483292
[TBL] [Abstract][Full Text] [Related]
5. Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy).
Tahara M; Matsuoka T; Yokoi T; Tasaka K; Kurachi H; Murata Y
Fertil Steril; 2000 Apr; 73(4):799-804. PubMed ID: 10731543
[TBL] [Abstract][Full Text] [Related]
6. Retreatment with nafarelin for recurrent endometriosis symptoms: efficacy, safety, and bone mineral density.
Hornstein MD; Yuzpe AA; Burry K; Buttram VC; Heinrichs LR; Soderstrom RM; Steinberger E; Lin JS
Fertil Steril; 1997 Jun; 67(6):1013-8. PubMed ID: 9176437
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis.
Kiilholma P; Tuimala R; Kivinen S; Korhonen M; Hagman E
Fertil Steril; 1995 Nov; 64(5):903-8. PubMed ID: 7589632
[TBL] [Abstract][Full Text] [Related]
8. Treatment with nafarelin for endometriosis in young women. Efficacy, safety and lipid metabolism. Niigata Nafarelin Study Group.
Kurabayashi T; Takakuwa K; Tanaka K
J Reprod Med; 2000 Jun; 45(6):454-60. PubMed ID: 10900577
[TBL] [Abstract][Full Text] [Related]
9. Impact of nafarelin and leuprolide for endometriosis on quality of life and subjective clinical measures.
Zhao SZ; Kellerman LA; Francisco CA; Wong JM
J Reprod Med; 1999 Dec; 44(12):1000-6. PubMed ID: 10649809
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain.
Hornstein MD; Yuzpe AA; Burry KA; Heinrichs LR; Buttram VL; Orwoll ES
Fertil Steril; 1995 May; 63(5):955-62. PubMed ID: 7720940
[TBL] [Abstract][Full Text] [Related]
11. Pain of endometriosis: effects of nafarelin and danazol therapy.
Adamson GD; Kwei L; Edgren RA
Int J Fertil Menopausal Stud; 1994; 39(4):215-7. PubMed ID: 7951404
[TBL] [Abstract][Full Text] [Related]
12. Pre or post-operative medical treatment with nafarelin in stage III-IV endometriosis: a French multicenter study.
Audebert A; Descamps P; Marret H; Ory-Lavollee L; Bailleul F; Hamamah S
Eur J Obstet Gynecol Reprod Biol; 1998 Aug; 79(2):145-8. PubMed ID: 9720832
[TBL] [Abstract][Full Text] [Related]
13. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial.
Henzl MR; Corson SL; Moghissi K; Buttram VC; Berqvist C; Jacobson J
N Engl J Med; 1988 Feb; 318(8):485-9. PubMed ID: 2963213
[TBL] [Abstract][Full Text] [Related]
14. Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis.
Hornstein MD; Hemmings R; Yuzpe AA; Heinrichs WL
Fertil Steril; 1997 Nov; 68(5):860-4. PubMed ID: 9389816
[TBL] [Abstract][Full Text] [Related]
15. Changes in quality of life after hormonal treatment of endometriosis.
Bergqvist A; Theorell T
Acta Obstet Gynecol Scand; 2001 Jul; 80(7):628-37. PubMed ID: 11437721
[TBL] [Abstract][Full Text] [Related]
16. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration.
Taga M; Minaguchi H
Acta Obstet Gynecol Scand; 1996 Feb; 75(2):162-5. PubMed ID: 8604604
[TBL] [Abstract][Full Text] [Related]
17. Low dose intranasal nafarelin for the treatment of endometriosis.
Jacobson J; Harris SR; Bullingham RE
Acta Obstet Gynecol Scand; 1994 Feb; 73(2):144-50. PubMed ID: 8116353
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel).
Adamson GD; Heinrichs WL; Henzl MR; Yuzpe AA; Bergquist C; Jacobson JJ; Eriksson S; Kwei L; Gilbert SM
Am J Obstet Gynecol; 1997 Dec; 177(6):1413-8. PubMed ID: 9423744
[TBL] [Abstract][Full Text] [Related]
19. Nafarelin therapy in endometriosis: long-term effects on bone mineral density.
Orwoll ES; Yuzpe AA; Burry KA; Heinrichs L; Buttram VC; Hornstein MD
Am J Obstet Gynecol; 1994 Nov; 171(5):1221-5. PubMed ID: 7977523
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy and safety of nafarelin in treating genital endometriosis].
Nikolov A; Karag'ozov I; Novachkov V
Akush Ginekol (Sofiia); 1996; 35(1-2):63-6. PubMed ID: 8967550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
